188bet博金宝官方网站Agilent Technologies,Inc。


"The Resolution Bioscience team and powerful technology are strategic and important additions to Agilent’s growing business in precision oncology solutions,” said Mike McMullen, Agilent president and CEO. “This also accelerates our work to more broadly deliver precision oncology testing for patients worldwide with NGS-based diagnostic kits. We’re excited to have Resolution Bioscience joining with us to expand our work in the fight against cancer."


此新闻稿包含1934年证券交易所所定义的前瞻性陈述,须遵守其中创建的安全港。本文包含的前瞻性陈述包括但不限于关于收购的能力和专业知识的陈述,提供行业要求,加速增长和收益影响的能力。这些前瞻性陈述涉及风险和不确定性,可能导致安捷伦结果与管理层目前的预期实质性不同。188bet博金宝官方网站这些风险和不确定性包括但不限于将决议生物科学的业务与安捷伦一起集成,留住关键员工,满足客户预期,实现联合国企业的效率,实现预期的税收福利。188bet博金宝官方网站此外,其他风险在运行其运营中的安捷伦面部包括通过商业周期成功188bet博金宝官方网站执行的能力;能够满足和实现其成本减少目标的好处,并以其他方式成功地调整其成本结构,以继续进行业务条件的变化;正在进行的竞争,定价和严重的压力;我们的成本削减计划将损害我们开发产品的能力并保持竞争力并有效运营的风险;地缘政治的不确定性和全球经济条件对我们的运营,市场和我们进行业务的能力的影响;改善资产绩效的能力,以适应需求变化; the ability of our supply chain to adapt to changes in demand; the ability to successfully introduce new products at the right time, price and mix; the ability of Agilent to successfully integrate recent acquisitions; the ability of Agilent to successfully comply with certain complex regulations; and other risks detailed in Agilent's filings with the Securities and Exchange Commission, including our quarterly report on Form 10-Q for the quarter ended Jan. 31, 2021. Forward-looking statements are based on the beliefs and assumptions of Agilent's management and on currently available information. Agilent undertakes no responsibility to publicly update or revise any forward-looking statement.